A number of clinical trials with PI3K/mTOR-targeted therapies in combination with CDK4/6 inhibitors for use in advanced HER2+/− breast cancer are ongoing [reviewed in 191], as those that are biomarker-driven in order to assess what agents would be beneficial to patients as second-line therapeutic regimens. This evidence concerns the gene ERBB2 and breast cancer.